| Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing |
2020-11-01 |
| Molecular Partners–Novartis: investment, 202010 acquisition CHF40m ordinary shares at CHF23/share by Novartis resulting in 6% shareholding |
2020-10-28 |
| Novartis–Molecular Partners: DARPins, 202010– license option + collab CHF20m upfront + CHF150m milestones + royalties developm DARPins for COVID-19 |
2020-10-28 |
| Sidekick Health–SEVERAL: investment, 202010 financing round Series A $20m led by Wellington Partners + Asabys Partners |
2020-10-28 |
| TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly |
2020-10-27 |
| TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund |
2020-10-27 |
| TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly |
2020-10-27 |
| AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones |
2020-10-26 |
| Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec |
2020-10-26 |
| MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs |
2020-10-26 |
| Araris Biotech–4BIO Ventures: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl new + co-investor 4BIO Capital |
2020-10-22 |
| Araris Biotech–Bellevue: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl new + lead investor Pureos Bioventures |
2020-10-22 |
| Araris Biotech–btov Partners: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl new + co-investor btov Partners |
2020-10-22 |
| Araris Biotech–Redalpine: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl existing + co-investor Redalpine |
2020-10-22 |
| Araris Biotech–Schroders: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl existing + co-investor Schroders Adveq |
2020-10-22 |
| Araris Biotech–SEVERAL: investment, 202010 seed financing round 2nd closing adding CHF12.7m bringing total round to CHF15.2m |
2020-10-22 |
| Araris Biotech–VI Partners: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl existing + co-investor VI Partners |
2020-10-22 |
| Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva |
2020-10-20 |
| ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group |
2020-10-20 |
| Immunic–EU (govt): credit, 202010– up to €24.5m venture loan in 3 tranches from EIB to develop IMU-838 for moderate Covid-19 |
2020-10-20 |
| Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners |
2020-10-19 |
| Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF |
2020-10-19 |
| Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures |
2020-10-19 |
| Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital |
2020-10-19 |
| Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec |
2020-10-19 |
| Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv |
2020-10-19 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors |
2020-10-19 |
| Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III |
2020-10-19 |
| Azitra–Bayer: investment, 202010 financing round Series B totalling $17m incl $8m from lead investor Leaps by Bayer |
2020-10-15 |
| Azitra–SEVERAL: investment, 202010 financing round Series B $17m led by Leaps by Bayer |
2020-10-15 |
| VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors |
2020-10-15 |
| RayzeBio–SEVERAL: investment, 202010 financing round Series A $45m co-led by venBio Partners + Versant Ventures |
2020-10-14 |
| Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds |
2020-10-13 |
| Chord Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum |
2020-10-13 |
| Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink |
2020-10-13 |
| Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund |
2020-10-13 |
| Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds |
2020-10-13 |
| Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital |
2020-10-12 |
| Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners |
2020-10-12 |
| Sensei Biotherapeutics–Angermayer Group: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Apeiron Investment Group |
2020-10-07 |
| Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures |
2020-10-07 |
| Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis |
2020-10-06 |
| Heartbeat Medical–btov Partners: investment, 202010 financing round Series A totalling €5m incl new + co-lead investor btov Partners |
2020-10-05 |
| Heartbeat Medical–High-Tech Gründerfonds: investment, 202010 financing round Series A totalling €5m incl existing + co-investor HTGF |
2020-10-05 |
| Heartbeat Medical–Holtzbrinck: investment, 202010 financing round Series A totalling €5m incl existing + co-lead investor HV Holtzbrinck Ventures |
2020-10-05 |
| Heartbeat Medical–SEVERAL: investment, 202010 financing round Series A €5m co-led by btov Partners + HV Holtzbrinck Ventures + incl HTGF |
2020-10-05 |
| BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED |
2020-10-02 |
| ECBF–Corbion: investment, 201911–202010 first closing totalling €82m incl co-investor Corbion NV |
2020-10-01 |
| ECBF–Hettich Beteiligungen: investment, 201911–202010 first closing totalling €82m incl co-investor Dr Hettich Beteiligungen GmbH |
2020-10-01 |
| ECBF–PreZero International: investment, 201911–202010 first closing totalling €82m incl co-investor PreZero International GmbH |
2020-10-01 |
| PeelPioneers–ECBF: investment, 202010 investment by ECBF in PeelPioneers BV |
2020-10-01 |
| Prolupin–ECBF: investment, 202010 investment by ECBF in Prolupin GmbH |
2020-10-01 |
| Sophia Genetics–ACE & Company: investment, 202010 financing round Series F totalling $110m incl new + co-investor ACE & Co |
2020-10-01 |
| Sophia Genetics–Alychlo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Alychlo |
2020-10-01 |
| Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon |
2020-10-01 |
| Sophia Genetics–Credit Suisse: investment, 202010 financing round Series F totalling $110m incl co-investor Credit Suisse |
2020-10-01 |
| Sophia Genetics–Endeavour Vision: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Endeavour Vision |
2020-10-01 |
| Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth |
2020-10-01 |
| Sophia Genetics–Famille C Invest: investment, 202010 financing round Series F totalling $110m incl new + co-investor Famille C Invest |
2020-10-01 |
| Sophia Genetics–Generation Investment Management: investment, 202010 financing round Series F totalling $110m incl existing + co-investor GIM |
2020-10-01 |
| Sophia Genetics–Hitachi: investment, 202010 financing round Series F totalling $110m incl co-lead investor Hitachi Ventures |
2020-10-01 |
| Sophia Genetics–Pictet: investment, 202010 financing round Series F totalling $110m incl co-investor Pictet Group |
2020-10-01 |
| Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures |
2020-10-01 |
| Sophia Genetics–Swisscom: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Swisscom Ventures |
2020-10-01 |
| Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR |
2020-10-01 |
| Integrated Proteomics Applications–Bruker: investment, 202009 acquisition €na of assets by Bruker |
2020-09-30 |
| Vedere Bio–Novartis: investment, 202009 acquisition $150m upfront + $130m milestones with some assets spun out before into Vedere BIo II |
2020-09-30 |
| Dewpoint Therapeutics–ARCH Venture: investment, 202009 financing round Series B totalling $77m incl lead investor ARCH Venture Partners |
2020-09-29 |
| Dewpoint Therapeutics–Bayer: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Leaps by Bayer |
2020-09-29 |
| Dewpoint Therapeutics–Bellco Capital: investment, 202009 financing round Series B totalling $77m incl new + co-investor Bellco Capital |
2020-09-29 |
| Dewpoint Therapeutics–EcoR1 Capital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor EcoR1 Capital |
2020-09-29 |
| Dewpoint Therapeutics–Innovation Endeavors: investment, 202009 financing round Series B totalling $77m incl existing + co-investor IE |
2020-09-29 |
| Dewpoint Therapeutics–Maverick Ventures: investment, 202009 financing round Series B totalling $77m incl new + co-investor Maverick Ventures |
2020-09-29 |
| Dewpoint Therapeutics–Polaris Partners: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Polaris Partners |
2020-09-29 |
| Dewpoint Therapeutics–Samsara BioCapital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Samsara BioCapital |
2020-09-29 |
| Dewpoint Therapeutics–SEVERAL: investment, 202009 financing round Series B $77m led by ARCH Venture Partners |
2020-09-29 |
| Kurma–SEVERAL: investment, 202009 first closing €50m of Kurma Diagnostics 2 Fund (KDx2) |
2020-09-29 |
| Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL |
2020-09-28 |
| XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside |
2020-09-28 |
| XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG |
2020-09-28 |
| Galecto–HBM: investment, 202009 financing round totalling $64m incl existing + co-investor HBM Healthcare Investments |
2020-09-25 |
| Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures |
2020-09-25 |
| Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group |
2020-09-25 |
| Mosa Meat–Blue Horizon Ventures: investment, 202009 financing round Series B 1st closing totalling $55m incl new + lead investor Blue Horizon Ventures |
2020-09-25 |
| Mosa Meat–Merck (DE): investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor M Ventures |
2020-09-25 |
| Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures |
2020-09-25 |
| Monte Rosa Therapeutics–1AB Media: public relations, 202009 service existent by 1AB Media |
2020-09-24 |
| Monte Rosa Therapeutics–Aisling Capital: investment, 202009 financing round Series B totalling $96m incl new + lead investor Aisling Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Alphabet: investment, 202009 financing round Series B totalling $96m incl new + co-investor GV |
2020-09-24 |
| Monte Rosa Therapeutics–Amzak Health: investment, 202009 financing round Series B totalling $96m incl new + co-investor Amzak Health |
2020-09-24 |
| Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor CAM |
2020-09-24 |
| Monte Rosa Therapeutics–Casdin Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Casdin Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Cormorant Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor Cormorant |
2020-09-24 |
| Monte Rosa Therapeutics–HBM: investment, 202009 financing round Series B totalling $96m incl new + co-investor HBM Healthcare Investments |
2020-09-24 |
| Monte Rosa Therapeutics–New Enterprise Associates: investment, 202009 financing round Series B totalling $96m incl existing + co-investor NEA |
2020-09-24 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Sixty Degree Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Versant Ventures: investment, 202009 financing round Series B totalling $96m incl existing + co-investor Versant Ventures |
2020-09-24 |
| AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP |
2020-09-23 |
| Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund |
2020-09-23 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 17 18 19 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
